 Shares of dermatology biopharma Arcutis Biotherapeutics, Inc. fell 16 the day after receiving its first FDA approval for ZORYVE roflumilast in the treatment of plaque psoriasis. The market seemed to be anticipating a secondary offering, which was executed three days later at 20 per share, likely obviating the need to ever return to the capital markets. 